TOP TEN perturbations for Q96JE7 (Homo sapiens)

Organism: Homo sapiens
Gene: Q96JE7
Selected probe(set): 1555289_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q96JE7 (1555289_at) across 5961 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-1.0239716
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-0.93037224
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-0.7727003
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-0.71960545
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

engineered skin substitute study 2 (early) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):0.67647076
Number of Samples:6 / 2
Experimental engineered skin substitute study 2 (early)
Human skin substitutes tissue samples collected after 3 and 7 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.

small cell lung cancer study 4 (XCL from CDX) / small cell lung cancer study 4 (cell line)

Relative Expression (log2-ratio):-0.67080975
Number of Samples:11 / 4
Experimental small cell lung cancer study 4 (XCL from CDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions.
Control small cell lung cancer study 4 (cell line)
Various small cell lung cancer (SCLC) publicly available cell lines samples.

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.64021826
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)

Relative Expression (log2-ratio):0.63229275
Number of Samples:34 / 19
Experimental diabetes type 2 study 27 (LCM)
Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year.
Control diabetes type 2 study 27 (enzymatic)
Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.607039
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 16 (glioblastoma) / normal brain tissue

Relative Expression (log2-ratio):-0.60470676
Number of Samples:12 / 2
Experimental glioma study 16 (glioblastoma)
Primary glioma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade IV).
Control normal brain tissue
Normal brain tissue sample from healthy donors.